Medvisis Switzerland AG announced that the company has entered into an exclusive licensing agreement with Formosa, a Taiwan-based Formosa Pharmaceuticals for exclusive rights to the commercialization of clobetasol propionate ophthalmic suspension, 0.05% (APP13007) for Switzerland and Liechtenstein on 28 Nov 2024.
Medvisis Switzerland AG and SLA Pharma, a UK based pharmaceutical company, signed a licencing agreement for 2% topical Diltiazem that gives Medvisis exclusive distribution rights for Switzerland and Liechtenstein on 18 Dec 2024.
Energenesis Biomedical, a Taiwan based company, partners with Medvisis Switzerland AG to expand into the European Market. Under the MoU agreement singed on 17 Mar 2025, the two companies will collaborate on multiple projects whereby Energenesis will grant Medvisis the commercialization rights in Switzerland and Europe for three of its innovative products covering two topical gels in the area of wound healing F703DFU, F703VLU as well as F701 a topical spray in the area of hair loss.
Medvisis Switzerland AG and Kedrion, an Italian based company signed a Distribution Agreement on 2 Jan 2026, whereby Medvisis acquired the distribution rights for the Kedrion Immunoglobulin and Albumin portfolio for Switzerland.